Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 5/20 | 0.82 |
| ▸ | HSD17B2 | P37059 | 4/20 | 0.82 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.80 |
| ▸ | SCD | O00767 | 5/20 | 0.76 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.74 |
| ▸ | NPC1 | O15118 | 2/20 | 0.72 |
| ▸ | RAB9A | P51151 | 2/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.72 |
| ▸ | MEN1 | O00255 | 1/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.72 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.70 |
| ▸ | SNCA | P37840 | 1/20 | 0.67 |
| ▸ | TP53 | P04637 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16554129 | 0.95 | HSD17B1 (0.75) | HSD17B1HSD17B2DYRK1ASCDLRRK2 | |
| SCHEMBL31024 | 0.92 | HSD17B1 (0.82) | HSD17B1HSD17B2DYRK1ASCDLRRK2 | |
| SCHEMBL31035 | 0.90 | HSD17B1 (1.00) | HSD17B1HSD17B2DYRK1ASCDLRRK2 | |
| SCHEMBL16554035 | 0.90 | HSD17B1 (0.76) | HSD17B1HSD17B2DYRK1ASCDLRRK2 | |
| SCHEMBL31006 | 0.87 | HSD17B1 (1.00) | HSD17B1HSD17B2DYRK1ASCDLRRK2 | |
| SCHEMBL19464560 | 0.86 | HSD17B1 (0.74) | HSD17B1HSD17B2DYRK1ASCDLRRK2 | |
| SCHEMBL13329360 | 0.86 | HSD17B1 (0.74) | HSD17B1HSD17B2DYRK1ASCDLRRK2 | |
| SCHEMBL12225869 | 0.86 | HSD17B1 (0.74) | HSD17B1HSD17B2DYRK1ASCDLRRK2 | |
| SCHEMBL12199347 | 0.86 | HSD17B1 (0.76) | HSD17B1HSD17B2DYRK1ASCDLRRK2 | |
| SCHEMBL12199323 | 0.86 | HSD17B1 (0.76) | HSD17B1HSD17B2DYRK1ASCDLRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2609089-A1 | SELECTIVE 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | Universität des Saarlandes (DE) | 2013-07-03 | — | — | EP | claimed |
| WO-2012025638-A1 | SELECTIVE 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | Universität des Saarlandes (DE) | 2012-03-01 | — | — | WO | claimed |
| EP-2609089-A1 | SELECTIVE 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | Universität des Saarlandes (DE) | 2013-07-03 | — | — | EP | disclosed |
| WO-2012025638-A1 | SELECTIVE 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | Universität des Saarlandes (DE) | 2012-03-01 | — | — | WO | disclosed |
| EP-2376463-A1 | BENZOTHIAZOLE AMIDES FOR DETECTION OF AMYLOID BETA | Bayer Pharma Aktiengesellschaft (DE) | 2011-10-19 | — | — | EP | disclosed |
| US-20110243846-A1 | BENZOTHIAZOLE AMIDES FOR DETECTION OF AMYLOID BETA | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-10-06 | — | — | US | disclosed |
| WO-2010066357-A1 | BENZOTHIAZOLE AMIDES FOR DETECTION OF AMYLOID BETA | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110243846-A1 | BENZOTHIAZOLE AMIDES FOR DETECTION OF AMYLOID BETA | APP, APBA1, BACE1 | HSD17B1 3226/4885HSD17B2 3825/4885DYRK1A 4687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.